stockrowVera Therapeutics, Inc.
VERA Healthcare Biotechnology
- EPS
- −26.7%
- Free cash flow
- −82.5%
- Total debt
- +1.03%
Quarter to June 2026, against a year earlier
Follow VERA
Alert me
Vera Therapeutics, Inc. (VERA) Return on assets
Vera Therapeutics, Inc.'s return on assets over the twelve months to 30 June 2026 was −72.3%, down 29.2 percentage points from fiscal 2025 (−43.1%). Over the past ten years it has ranged from −440.6% (fiscal 2019) to −36.6% (fiscal 2024); the current reading is higher than 86% of that period. That is below the Biotechnology industry median of −45.6% and below the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −43.1% | (6.49) |
| FY2024 | −36.6% | 25.93 |
| FY2023 | −62.5% | 20.23 |
| FY2022 | −82.8% | (35.61) |
| FY2021 | −47.2% | 131.08 |
| FY2020 | −178.2% | 262.35 |
| FY2019 | −440.6% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | 46.5% |
| ADMA ADMA Biologics Inc compare | 28.0% |
| VCEL Vericel Corporation compare | 6.86% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.00% |
| PVLA Palvella Therapeutics, Inc. compare | −37.7% |
| CLDX Celldex Therapeutics, Inc. compare | −40.8% |
| IMNM Immunome, Inc. compare | −59.0% |
| VERA Vera Therapeutics, Inc. | −72.3% |
| BHVN Biohaven Ltd. compare | −161.3% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)